- Volume is elevated versus the 13-week average, confirming attention.
PASW
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Ping An Biomedical Co., Ltd. · Consumer Cyclical · Textile Manufacturing
Latest close
0.12 USD
-15.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is - below the Trend Line and sits at 13.4% of its 52-week range. The latest completed week returned -15.0%, after a -22.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100.
Setup score
30
out of 100
Latest Close
0.12 USD
24 Jul 2026
1W Return
-15.0%
latest completed week
4W Return
-22.0%
short-term follow-through
12W Return
-
quarterly tape
Trend Breadth
0.0%
0 of 7 weeks active
Volume Ratio
5.2x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 40.15% based on similar historical setup states.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-15.0%
Latest completed week; four-week move -22.0%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.15%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
53/100
34 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 13.4% of its 52-week range. The latest completed week returned -15.0%, after a -22.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 5.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0012-week average 0.00
12-week confirmation
Trend active0/7Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/7Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/7Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -22.0% over four weeks, - over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 30 Sep 2025
Field coverage 64%
Model confidence 43%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength44/100Blend of value, momentum, and quality. Underlying universe rank 57; rank 1 is best.
Value47/100Relative valuation strength. Underlying universe rank 54; rank 1 is best.
Quality45/100Profitability and accounting quality. Underlying universe rank 56; rank 1 is best.
Momentum47/100Medium-term price momentum. Underlying universe rank 54; rank 1 is best.
Growth47/100Revenue and earnings growth. Underlying universe rank 54; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.5x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -26.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 2.8% Gross profit retained from each unit of revenue.
- Operating margin
- -42.1% Operating profit retained from revenue.
- Free-cash-flow margin
- -18.8% Free cash flow generated from revenue.
- Return on invested capital
- -19.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -61.0% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -143.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment53/100
Weighted news tone is neutral across 34 relevant articles.
8 positive · 20 neutral · 6 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-42.1%Distance below the 52-week high.
13-week volatility7.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
12 Jun
10 Jul
24 Jul
Weeks higher2 of 64 weeks finished lower.
Best week+6.0%Week of 19 Jun.
Worst week-15.0%Week of 24 Jul.
Latest week-15.0%Week of 24 Jul.
Shape of recent returns
Strong gains1
Modest gains1
Flat weeks0
Modest losses1
Sharp losses3
Recent vol7.0%13-week weekly-return volatility.
Base vol7.0%52-week weekly-return volatility.
Up/down split2/4Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Consumer Cyclical
4-week rank- / 100
Group average-0.8%
Trend breadth36.0%
Trend36.0%active weekly trend signals
MD53.0%positive activity pressure
RS31.0%positive relative leadership
Four-week leaders
IndustryUS Textile Manufacturing
4-week rank4 / 4
Group average5.8%
Trend breadth50.0%
Trend50.0%active weekly trend signals
MD75.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape31/100
Trend, activity pressure, participation, and risk combine to a 31/100 tape read.
Indicator analysis14/100Latest 12-week confirmation: trend 0/7, activity pressure 0/7, relative leadership 0/7.
Activity pressure 0.00; 2 reversal markers Next-Week ExpectancyNegative 40.15%Next-week expectancy is negative with a 40.15% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment53/100Weighted news tone is neutral across 34 relevant articles.
Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 0.12 USD | -15.0% | - | 0.16 USD | 0.00 | - | 22.8M | Off |
| 17 Jul 2026 | 0.15 USD | -7.0% | - | 0.16 USD | 0.00 | - | 201.1K | Off |
| 10 Jul 2026 | 0.16 USD | -2.0% | - | 0.16 USD | 0.00 | - | 481.1K | Off |
| 3 Jul 2026 | 0.16 USD | 0.6% | - | 0.17 USD | 0.00 | - | 369.2K | Off |
| 26 Jun 2026 | 0.16 USD | -10.3% | - | 0.17 USD | - | - | 608.2K | Off |
| 19 Jun 2026 | 0.18 USD | 6.0% | - | 0.17 USD | - | - | 683.9K | Off |
| 12 Jun 2026 | 0.17 USD | - | - | 0.17 USD | - | - | 5.3M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.